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Background
Pollen Food(Oral allergy) Syndrome (PFS) is a food
allergy which is caused by cross-reactivity between inha-
lant pollen allergens and food allergens, causing mild to
severe symptoms upon ingestion of the cross-reacting
foods. PFS has a high and increasing prevalence in pol-
len-allergic patients. The role of pollen-specific immu-
notherapy in improving clinical outcomes for patients
with PFS has not been established. To date, there are no
systematic reviews which have been identified in the
background research in this field. Aim of the review was
to evaluate the evidence and determine whether pollen-
specific immunotherapy clinically improves symptoms of
PFS in pollen-allergic patients.
Methods
This review was undertaken in accordance with the
Cochrane Handbook for Systematic Reviews and
PRISMA. Comprehensive literature search was con-
ducted to identify suitable studies including randomised
controlled trials (RCTs), observational studies and non-
randomised trials (NRCTs) which investigated the role
of a pollen-specific immunotherapy for a minimum per-
iod of 1 year in the clinical improvement of PFS in pol-
len-allergic patients. Quality assessments were made for
each study using two instruments to ensure methodolo-
gical rigour. Raw outcome data was extracted and
analysed for each of the study designs. Sensitivity and
heterogeneity analysis were performed.
Results
11 trials (506 patients) met the inclusion criteria. 4 were
RCTs (n=120), 2 were NRCTs (n=102) and 5 were obser-
vational before-and-after (immunotherapy) studies
(n=156). A total of 378 patients were analysed. 290 had
immunotherapy and 88 did not. 156 of those patients
receiving immunotherapy served as their own controls in
the observational studies in the data analysis. Quality
assessments demonstrated that several studies had limita-
tions and were not all of strong methodological rigour.
Most studies were underpowered. This meta-analysis
shows trends favouring immunotherapy. However, there
was considerable heterogeneity in the RCTs. The RCTs
showed an overall pooled odds ratio (OR) of 0.36 (95%
confidence interval [CI] 0.07, 2.00) favouring immu-
notherapy. In the sensitivity analysis, the effect of remov-
ing the outlier study resulted in a statistically significant
OR of 0.19 (95% CI 0.05, 0.74) and a reduction in hetero-
geneity. For NRCTs, the pooled OR was 0.01 (95% CI
0.00, 0.05) and for Observational studies, the OR was
0.02 (95% CI 0.01, 0.07), favouring immunotherapy.
Conclusions
This meta-analysis demonstrates potentially favourable
effects of pollen-specific immunotherapy in improving
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clinical outcomes for PFS patients. However, the inade-
quacies of the reported trials analysed limit the reliabil-
ity of these findings. Further research is warranted on
the basis of these results, using robust clinical studies.
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